Targeting the Fibroblast Growth Factor System in Prostate Cancer
Author Information
Author(s): Gowardhan B, Douglas D A, Mathers M E, McKie A B, McCracken S R C, Robson C N, Leung H Y
Primary Institution: Urology Research Group, Northern Institute for Cancer Research, University of Newcastle
Hypothesis
Can abnormal FGFR expression in prostate cancer be targeted for therapy?
Conclusion
The study supports the fibroblast growth factor system as a valid target for therapy in prostate cancer.
Supporting Evidence
- FGFR4 expression was significantly upregulated in prostate cancer compared to benign prostatic hyperplasia.
- A significant positive correlation between FGFR4 expression and Gleason score was noted.
- FGFR4 overexpression was associated with decreased disease-specific survival.
Takeaway
Researchers found that a specific protein related to prostate cancer can be targeted to help treat the disease better.
Methodology
The study examined FGFR3 and FGFR4 expression in prostate cancer specimens and tested the effects of combining soluble FGFR with chemotherapy and radiation on cancer cell growth.
Limitations
The study was limited to archival specimens and may not represent all prostate cancer cases.
Participant Demographics
The cancer group had a mean age of 71 years, with a range from 56 to 86 years.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website